
Nitrile gloves firm Enliva to invest Rs 100 crore to scale operations
Live Events
The Indian market is seeing a rise in the demand for nitrile gloves. According to Grand View Research, the market for nitrile gloves , crucial for handling hazardous chemicals, is projected to grow from $12.71 billion in 2024 to $20.71 billion by 2030, at an 8.5% CAGR (2025-2030).'The demand is being driven not just by healthcare, but by broader shifts in hygiene protocols across pharma, food, and industrial sectors. Asia-Pacific is leading this growth, with North America and Europe continuing to set the bar on compliance and quality,' said K. Anindith Reddy, Co-Founder and Managing Director, Enliva Enliva, a nitrile manufacturing company based out of Hyderabad, produces 1 million nitrile gloves daily and about 300 million nitrile gloves annually. The company is now set to invest Rs 100 crore to scale up operations. It is looking to add two lines to their current facility in Visakhapatnam and a new plant under evaluation for 2028.'Our goal is to build distributed, resilient capacity and respond faster to global demand shifts. We're also exploring strategic acquisitions and partnerships. Most importantly, this investment will deepen our R&D, building on our recent milestone of launching India's first accelerator-free nitrile glove,' he said.Enliva was founded in the middle of the Covid-19 pandemic in 2021 by Reddy, a member of Apollo Hospital Group's promoter family, and his associates Shaaz Mehmood and Ishaan Dodhiwala. During that period, there were many gaping holes in the healthcare supply chain, an important one being India's dependence on imported medical essentials like nitrile gloves.It wasn't just the shortage they noticed, but also the inferior, often rejected products being routed into the Indian market.'In 2021, we laid the groundwork for Wadi Surgicals (Envila's parent firm), our manufacturing unit inside the Andhra Pradesh Medtech Zone in Visakhapatnam. By 2022, we commissioned India's first double-former nitrile dipping line, designed for both speed and precision. May 2023 was a key milestone-our first line went live,' he said.He pointed out that India is at a critical inflection point and is one of the top consumer bases globally for nitrile gloves, with annual demand exceeding 11 billion gloves.The nature of demand is changing as customers are increasingly looking for skin-safe, accelerator-free, globally compliant gloves. With evolving regulations, especially post-COVID, the need for high-performance, sustainably manufactured gloves is no longer optional, it's expected, Reddy said.'However, we still depend on imports for about 75% of our needs. That gap signals a massive opportunity for reliable, high-quality local production. We believe India can make for the world,' he said.One of the core issues plaguing the Indian glove industry is the lack of regulatory enforcement, he pointed out. While quality-conscious manufacturers invest in BIS-certified, skin-safe, non-chlorinated gloves, the market continues to be flooded with low-cost imports, many of which are chlorinated, poorly stored, or chemically unstable. 'These gloves often degrade quickly, cause skin irritation, and compromise long-term usability, especially for healthcare workers who wear them for hours each day,' he said.Another issue is the inverted duty structure under the ASEAN Free Trade Agreement, which further complicates things. Reddy explained that this agreement allows zero-duty imports from countries like Malaysia and Thailand, where manufacturers, backed by subsidies, can undercut Indian producers who are investing in compliance, R&D, and ethical manufacturing practices.'This makes it harder to compete on price without compromising on quality. We're tackling this by staying focused on building a differentiated, high-performance product. At Enliva, we've invested in producing accelerator-free nitrile gloves that are more durable, gentler on skin, and aligned with evolving global norms. We're also working actively with policymakers to push for Quality Control Orders, enforce BIS standards, and introduce anti-dumping duties to protect both consumers and compliant manufacturers,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

First Post
21 minutes ago
- First Post
Covid-19 now just like any other respiratory illness, predominant in India after recent surge: Expert
SARS-CoV-2, the virus that causes Covid-19 disease, is just like any other respiratory illness now and there is no possibility of another catastrophic wave like the one driven by Delta variant in 2021, according to Soumya Swaminathan, a former Chief Scientist at the World Health Organization (WHO). read more At present, 'LF.7' and 'NB.1.8' — both descendants of the 'JN.1' variant — are the main variants of the COVID-19-causing virus circulating in Singapore. AP File Soumya Swaminathan, a former Chief Scientist at the World Health Organization (WHO), has said that SARS-CoV-2, the virus that causes Covid-19 disease, is now just like any other respiratory virus and there is no need to panic at the moment. In recent weeks, Covid-19 cases have risen in India. As per the latest information, there are 3,961 active Covid-19 cases in the country, with 203 new cases and four deaths being reported in the previous 24 hours. STORY CONTINUES BELOW THIS AD In an interview with CNN-News 18, Swaminathan said that the SARS-CoV-2, just like any other virus, is bound to periodic surges every six to eight months and the ongoing spike in cases is a result of such a periodic surge. She went on to compare it with influenza virus. 'It has been around now for five years. It is of course constantly mutating and changing like other viruses. And, just like we get every year a spike of influenza cases at certain seasons, we have also now started seeing that periodically, maybe every six to eight months or so, there is a rise in Covid cases,' said Swaminathan, who also served as the Director General of Indian Council of Medical Research (ICMR) during 2015-17. Swaminathan further said that there was no chance of another catastrophic wave of Covid-19 like the Delta variant's wave of 2021. Swaminathan noted that influenza virus was the predominant respiratory infection for most of the year and it was only in April and May that Covid-19 over influenza. She said that it is likely to happen now as Covid-19 has become just another viral infection now. Swaminathan said, 'It's likely that every few months or once a year, we will see this type of thing happening in the future. The good thing is, of course, that we all have immunity now, both from vaccination and from natural infections that many of us have had in the last few years. And, so, what you're seeing now is a mild disease mostly, even though people are testing and reporting positivity, you find that hospitalisations are very few.' STORY CONTINUES BELOW THIS AD While there is no need to panic, people with higher risk of sickness should take the usual precautions, said Swaminathan. Those with higher risk include people with compromised immune systems, pre-existing health conditions, and older people, according to Swaminathan.


India.com
27 minutes ago
- India.com
Bad news for Noel Tata, this company reports 9% decline in sales, share price fell by…
Tata Motors on Sunday reported a 9 per cent year-on-year decline in total sales at 70,187 units in May. The Mumbai-based auto major had reported total sales of 76,766 units in May 2024. Domestic sales declined 10 per cent year-on-year to 67,429 units, as compared to 75,173 units in the year-ago period Tata Motors said in a statement. Total passenger vehicle sales declined 11 per cent year-on-year to 42,040 units in May. Commercial vehicles sales stood at 28,147 units, as compared to 29,691 units, a dip of 5 per cent. At 9:20 am, shares of the company were trading at Rs 711, lower by 1.2 percent from the last close. Tata Motors declined 2 percent to Rs 707 in morning trade on June 2 after the report of dip in company's vehicle sales. Tata Motors shares are down 3 percent since the beginning of the year. The company reported a 51 percent fall in net profit in the quarter ended March 2025. It posted a consolidated net profit of Rs 17,407 crore in the same quarter last fiscal. Its consolidated total revenue from operations increased 0.4 percent at Rs 1,19,503 crore against Rs 1,19,033 crore in the year-ago period. However, the sales volumes at JLR rose 1.1 percent in the quarter, due to a strong demand for its SUVs in North America and Europe. Jefferies has given an 'underperform' rating on Tata Motors with a target price of Rs 630 per share. (With Inputs From PTI)


News18
27 minutes ago
- News18
French Firm Servier Drops Exclusive Deal For Selling High BP Drugs After Chemists' Pushback
Last Updated: After successful mediation by offline chemists, Servier promptly withdrew the agreement – which is seen as a positive step towards preserving the fairness of open trade practices. In a major development impacting the pharmaceutical distribution landscape in India, an Indian arm of French drugmaker Servier has officially withdrawn its exclusive distribution agreement for its anti-hypertensive product line, reverting to conventional distribution practices. The move comes after the apex lobby of offline chemists, All India Organisation of Chemists and Druggists (AIOCD), raised concerns, alleging the potential monopolistic implications of Servier's deal with Entero Healthcare, a supply chain specialist company. AIOCD represents more than 12 lakh chemists and distributors in India, pushing Servier to discontinue the arrangement of supplying certain products via Entero. The majority of the AIOCD's partners refused to sell the drugs sold by the French drugmaker. After facing industry pushback, in a letter dated May 26, 2025, Servier India informed its trade partners that it has 'discontinued exclusive distribution arrangement for anti-hypertensive range of products" with immediate effect. The letter has been seen by News18. This update follows a formal communication by AIOCD on May 28, addressing the issue. The letter detailed how many members of the organisation had expressed concerns over the exclusivity agreement, warning that it could lead to discriminatory trade practices, shortages in essential medications, and the formation of monopolistic structures within the pharmaceutical supply chain. AIOCD, in a letter, said that the organisation mediated with Servier to ensure a fair resolution. 'After successful mediation by AIOCD, the company has promptly withdrawn the said exclusive distribution agreement. This is a positive and encouraging step toward preserving the balance and fairness in our open trade practices," the letter read. The development is being seen as a victory for chemists and druggists across India, many of whom feared market distortions and reduced access to essential medicines due to exclusive arrangements. 'We have had fruitful discussions with AIOCD. Servier India is focused on improving patient access to our quality medicines. We will continue to engage constructively with all stakeholders," Aurelien Breton, managing director, Servier India told News18. Brenton told News18 that he is thankful to AIOCD 'for the constructive dialogue, which allowed us to resolve the matter amicably in the interest of the healthcare community and patients at large." 'Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world." Headquartered in France, Servier operates in around 140 countries. Sources close to the development told News18 that, 'Servier's management rushed the distributor appointment, with inadequate market assessment and due diligence. However, now, it has made right decision following the general rules of the Indian pharma trade market." First Published: June 02, 2025, 12:40 IST